Fundraising FoxMnemo Therapeutics
5 known investors
Find your way into Mnemo Therapeutics
Sign up to see every warm intro you have to Mnemo Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Mnemo Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Mnemo Therapeutics is a Paris-based clinical-stage biotech developing cell therapies using its EnfiniT epigenetic antigen discovery platform to target tumor-specific antigens for CAR-T therapies.
Investors · 5
How we know: Sofinnova Partners's portfolio page · prnewswire.com · Not right? Tell us
How we know: prnewswire.com · Not right? Tell us
How we know: funding news · prnewswire.com · Not right? Tell us
How we know: prnewswire.com · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$90M disclosed across 1 round · 2021
- $90MSeries AJun 2021 · 4 sources
Casdin Capital (lead), Sofinnova Partners (lead), Alexandria Venture Investments, Emerson Collective, Redmile
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Mnemo Therapeutics do?
- Mnemo Therapeutics is a Paris-based clinical-stage biotech developing cell therapies using its EnfiniT epigenetic antigen discovery platform to target tumor-specific antigens for CAR-T therapies.
- Who are Mnemo Therapeutics's investors?
- Mnemo Therapeutics's investors include Sofinnova Partners, Alexandria, Casdin Capital, REDMILE.
- How much funding has Mnemo Therapeutics raised?
- Mnemo Therapeutics has disclosed $90M raised across 1 round.